Targeting Protein Misfolding and Innovations in Hepatobiliary Disease with Rectify Pharma’s Dr. Pol Boudes

In this week’s episode of the Xtalks Life Science Podcast, host Ayesha Rashid, Senior Life Science Journalist at Xtalks, spoke with Pol Boudes, MD, Chief Medical Officer at Rectify Pharma. Rectify Pharma is a biotechnology company pioneering a positive functional modulators (PFM) platform to address the root causes of genetic and protein folding diseases in the liver, cardio-renal-metabolic and neurodegenerative spaces. The company’s lead program is in hepatobiliary diseases. Dr. Boudes has more than 30 years of R&D, clinical, medical affairs and biotech leadership experience. He is a board-certified physician in endocrinology and metabolic diseases with specialization in internal medicine and geriatric diseases. Before joining Rectify, Dr. Boudes served as Chief Medical Officer at Galectin Therapeutics and CymaBay Therapeutics, leading pipeline programs and supporting multiple financings. At Amicus Therapeutics, Dr. Boudes pioneered chaperone therapies for lysosomal storage disorders. Earlier in his career, he held senior international positions at Bayer, Wyeth-Ayerst Research (now Pfizer) and Roche, and he currently serves on the board of Protalix Biotherapeutics. Dr. Boudes received his MD from the University of Marseille, France. Tune in to hear about how innovation in hepatobiliary diseases is gaining new momentum, driven by novel approaches to correcting protein misfolding at its source. For more life science and medical device content, visit the Xtalks Vitals homepage. https://xtalks.com/vitals/ Follow Us on Social Media Twitter: https://twitter.com/Xtalks Instagram: https://www.instagram.com/xtalks/ Facebook: https://www.facebook.com/Xtalks.Webinars/ LinkedIn: https://www.linkedin.com/company/xtalks-webconferences YouTube: https://www.youtube.com/c/XtalksWebinars/featured